Publications by authors named "F Lot"
Background: The prevalence of syphilis, Chlamydia trachomatis (CT), and Neisseria gonorrhoeae (NG) in men who have sex with men (MSM) is very high. As these bacterial sexually transmitted infections (bSTIs) are frequently asymptomatic, they are often undiagnosed and therefore untreated. We aimed to characterize the profile of MSM who reported bSTI screening and diagnosis in the previous 12 months, and to identify the factors associated with a diagnosis of a bSTI among MSM in France.
View Article and Find Full Text PDFBackground And Objectives: In 2016, France allowed men who have sex with men (MSM) to donate blood if they had not had sex with men in the previous 12 months. In April 2020, this restriction was relaxed to 4 months due to the lack of negative impact observed on blood safety. This study assesses the impact of reducing this deferral period on epidemiological surveillance indicators.
View Article and Find Full Text PDFArticle Synopsis
- Syphilis cases among blood donors in France have been rising, with a significant uptick observed in 2022 compared to earlier years.
- Data from over 45 million donations (2007-2022) revealed that the infection rate was notably higher in males, particularly among men who have sex with men (MSM), whose risk factor percentage increased over time.
- A non-treponemic test (NTT) was used to assess infection recency, but the data were insufficient to reliably differentiate between recent and past infections among the syphilis-positive donors.
Article Synopsis
- Since 2022, Europe has identified 4 cases of extensively drug-resistant Neisseria gonorrhoeae, particularly sequence type 16406, which is resistant to ceftriaxone and has high resistance to azithromycin.
- In 2023, two new related cases were reported in France that share genetic links with the previous European cases and strains from Cambodia.
- This highlights growing concerns about the spread of drug-resistant gonorrhea in Europe and its potential global implications.
Given the World Health Organization's target to eliminate the hepatitis C virus (HCV) by 2030, we assessed the impact of French public policies and the COVID-19 pandemic on HCV testing and initiation of direct-antiviral agents (DAAs). Using the French National Health Data System, we identified individuals living in metropolitan France with at least one reimbursement for an anti-HCV test and those with a first delivery of DAAs between 1 January 2014 and 31 December 2021. During this period, the annual number of people tested increased each year between 3.
View Article and Find Full Text PDF